We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Original Investigation |

Association Between Changes in Coronary Artery Disease Progression and Treatment With Biologic Agents for Severe Psoriasis ONLINE FIRST

Kasper Fjellhaugen Hjuler, MD1; Morten Bøttcher, MD, PhD2; Christian Vestergaard, MD, PhD, DMSc1; Hans Erik Bøtker, MD, PhD3; Lars Iversen, MD, DMSc1; Knud Kragballe, MD, DMSc1
[+] Author Affiliations
1Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark
2Department of Internal Medicine, Cardiac Imaging Center, Hospital Unit West, Herning, Denmark
3Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark
JAMA Dermatol. Published online July 07, 2016. doi:10.1001/jamadermatol.2016.1984
Text Size: A A A
Published online

Importance  Inflammatory pathways of psoriasis share similarities with the mechanisms identified in atherosclerosis, and the association between psoriasis and cardiovascular disease due to accelerated coronary artery disease is well established. The effect of anti-inflammatory drugs on the development of coronary atherosclerosis remains essentially unknown.

Objective  To investigate the association of biological therapy with changes in coronary artery disease progression, measured by repeated coronary computed tomography (CT).

Design, Setting, and Participants  This single-center prospective, controlled, observer-blinded clinical study at a tertiary dermatology university hospital clinic enrolled patients with severe psoriasis initiating biological therapy and matched controls not receiving systemic therapy from April 11, 2011, through June 30, 2014.

Interventions  Biological therapy approved for psoriasis (adalimumab, etanercept, infliximab, ustekinumab) with the possibility to switch between treatments to ensure tight control of inflammation.

Main Outcomes and Measures  Patients underwent noncontrast coronary artery calcium (CAC) CT and contrast-enhanced coronary CT angiography at baseline and after 13 months of follow-up. Changes in CAC score, number of coronary plaques, severity of narrowing, composition, and vessel wall volume were measured.

Results  There were 28 treated patients (mean [SD] age, 49.2 [10.2] years; 71% men; mean [SD] Psoriasis Area Severity Index [PASI], 15.4 [4.3]) and 28 controls (mean [SD] age, 52.8 [10.6] years; 71% men; mean [SD] PASI, 12.4 [3.9]). The CAC scores remained stable in the intervention group (mean [SD] yearly CAC change, −16 [56]; P = .15) and progressed in the control group (14 [29]; P = .02) (intervention vs controls: P = .02). The number of segments with luminal abnormalities remained unchanged in both groups. The severity of luminal narrowing in the diseased segments was unchanged in the intervention group (Wilcoxon W = 76, n = 483, P = .39) but increased at follow-up in the control group (Wilcoxon W = 281, n = 414, P = .02). Automated vessel wall volume index remained unchanged from baseline to follow-up in the intervention group (mean [SD] baseline, 7.1 [1.5], follow-up, 7.1 [1.7]; P = .91), while controls demonstrated statistically nonsignificant progression (baseline, 8.3 [1.6], follow-up, 8.9 [2.2]; P = .06).

Conclusions and Relevance  Clinically effective treatment with biologic agents was associated with reduced coronary artery disease progression in patients with severe psoriasis. These findings support a beneficial effect of biologic anti-inflammatory agents in preventing cardiovascular disease progression in addition to disease control in inflammatory diseases.

Figures in this Article


Place holder to copy figure label and caption
Figure 1.
Psoriasis Area Severity Index (PASI) During Treatment With Biological Agents

Disease control was generally tight, with switch in biologic treatment when less than a 50% reduction in PASI was obtained or in case of adverse events. Symbols represent individual patients, and lines connect paired observations for each patient.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
Coronary Artery Calcium Scores at Baseline and Follow-up

The progression of coronary calcium scores from baseline to follow-up in both groups is shown. Results of repeated-measures statistics and between-group statistics are shown. Symbols represent individual patients, and lines connect paired observations for each patient.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 3.
Number of Segments With Luminal Abnormalities and Severity of Abnormalities at Baseline and Follow-up

A, Number of segments with luminal narrowing on a patient level at baseline and at follow-up. Lines symbolize a change in the number of segments with abnormalities for 1 or more patients. B, Severity of the luminal narrowing for all analyzable segments on an ordinal scale. Symbols represent individual segments, and lines represent the change in severity of luminal narrowing for 1 or more segments.

Graphic Jump Location




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections

Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice, 3rd ed
The Biological Agent